Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Therapeutic Equivalency
Conditions
Therapeutic Equivalency, Food
Trial Timeline
Oct 1, 2008 → Dec 1, 2008
NCT ID
NCT00807118About Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine
Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine is a phase 1 stage product being developed by Pfizer for Therapeutic Equivalency. The current trial status is completed. This product is registered under clinical trial identifier NCT00807118. Target conditions include Therapeutic Equivalency, Food.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01286454 | Phase 1 | Completed |
| NCT00807118 | Phase 1 | Completed |
Competing Products
11 competing products in Therapeutic Equivalency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939) | Johnson & Johnson | Phase 1 | 33 |
| Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection | Jiangsu Hengrui Medicine | Approved | 85 |
| Amifostine + Carboplatin + Paclitaxel | AstraZeneca | Phase 2 | 52 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| etynodiol diacetate + etynodiol diacetate | Pfizer | Phase 1 | 32 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| BAY98-7111 + Naproxen Sodium (Aleve, BAYH6689) + Diphenhydramine HCl + BAY98-7111 | Bayer | Phase 1 | 30 |
| Pravastatin + Pravastatin | Viatris | Phase 1 | 30 |
| Pravastatin + Pravastatin | Viatris | Phase 1 | 30 |
| Raxibacumab | Emergent BioSolutions | Phase 2/3 | 57 |